A 19-SNP coronary heart disease gene score profile in subjects with type 2 diabetes: the coronary heart disease risk in type 2 diabetes (CoRDia study) study baseline characteristics

Katherine E Beaney; Claire E Ward; Dauda A S Bappa; Nadine McGale; Anna K Davies; Shashivadan P Hirani; KaWah Li; Philip Howard; Dwaine R Vance; Martin A Crockard; John V Lamont; Stanton Newman; Steve E Humphries

doi:10.1186/s12933-016-0457-7

A 19-SNP coronary heart disease gene score profile in subjects with type 2 diabetes: the coronary heart disease risk in type 2 diabetes (CoRDia study) study baseline characteristics

Katherine E Beaney, Claire E Ward, Dauda A S Bappa, Nadine McGale, Anna K Davies, Shashivadan P Hirani, KaWah Li, Philip Howard, Dwaine R Vance, Martin A Crockard, John V Lamont, Stanton Newman, Steve E Humphries

Research output: Contribution to journal › Article (Academic Journal) › peer-review

8 Citations (Scopus)

Abstract

BACKGROUND: The coronary risk in diabetes (CoRDia) trial (n = 211) compares the effectiveness of usual diabetes care with a self-management intervention (SMI), with and without personalised risk information (including genetics), on clinical and behavioural outcomes. Here we present an assessment of randomisation, the cardiac risk genotyping assay, and the genetic characteristics of the recruits.

METHODS: Ten-year coronary heart disease (CHD) risk was calculated using the UKPDS score. Genetic CHD risk was determined by genotyping 19 single nucleotide polymorphisms (SNPs) using Randox's Cardiac Risk Prediction Array and calculating a gene score (GS). Accuracy of the array was assessed by genotyping a subset of pre-genotyped samples (n = 185).

RESULTS: Overall, 10-year CHD risk ranged from 2-72 % but did not differ between the randomisation groups (p = 0.13). The array results were 99.8 % concordant with the pre-determined genotypes. The GS did not differ between the Caucasian participants in the CoRDia SMI plus risk group (n = 66) (p = 0.80) and a sample of UK healthy men (n = 1360). The GS was also associated with LDL-cholesterol (p = 0.05) and family history (p = 0.03) in a sample of UK healthy men (n = 1360).

CONCLUSIONS: CHD risk is high in this group of T2D subjects. The risk array is an accurate genotyping assay, and is suitable for estimating an individual's genetic CHD risk. Trial registration This study has been registered at ClinicalTrials.gov; registration identifier NCT01891786.

Original language	English
Pages (from-to)	141
Journal	Cardiovascular Diabetology
Volume	15
Issue number	1
DOIs	https://doi.org/10.1186/s12933-016-0457-7
Publication status	Published - 3 Oct 2016

Keywords

Adult
Aged
Case-Control Studies
Coronary Artery Disease/diagnosis
Diabetes Mellitus, Type 2/diagnosis
Diabetic Angiopathies/diagnosis
Female
Gene Expression Profiling/methods
Genetic Association Studies
Genetic Markers
Genetic Predisposition to Disease
Humans
Male
Middle Aged
Oligonucleotide Array Sequence Analysis
Phenotype
Polymorphism, Single Nucleotide
Precision Medicine
Predictive Value of Tests
Pregnancy
Risk Assessment
Risk Factors
Time Factors
United Kingdom

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12933-016-0457-7

Handle.net

Persistent link

Cite this

Beaney, K. E., Ward, C. E., Bappa, D. A. S., McGale, N., Davies, A. K., Hirani, S. P., Li, K., Howard, P., Vance, D. R., Crockard, M. A., Lamont, J. V., Newman, S., & Humphries, S. E. (2016). A 19-SNP coronary heart disease gene score profile in subjects with type 2 diabetes: the coronary heart disease risk in type 2 diabetes (CoRDia study) study baseline characteristics. Cardiovascular Diabetology, 15(1), 141. https://doi.org/10.1186/s12933-016-0457-7

@article{4971916b611143e2a61858030c6a79a9,

title = "A 19-SNP coronary heart disease gene score profile in subjects with type 2 diabetes: the coronary heart disease risk in type 2 diabetes (CoRDia study) study baseline characteristics",

abstract = "BACKGROUND: The coronary risk in diabetes (CoRDia) trial (n = 211) compares the effectiveness of usual diabetes care with a self-management intervention (SMI), with and without personalised risk information (including genetics), on clinical and behavioural outcomes. Here we present an assessment of randomisation, the cardiac risk genotyping assay, and the genetic characteristics of the recruits.METHODS: Ten-year coronary heart disease (CHD) risk was calculated using the UKPDS score. Genetic CHD risk was determined by genotyping 19 single nucleotide polymorphisms (SNPs) using Randox's Cardiac Risk Prediction Array and calculating a gene score (GS). Accuracy of the array was assessed by genotyping a subset of pre-genotyped samples (n = 185).RESULTS: Overall, 10-year CHD risk ranged from 2-72 % but did not differ between the randomisation groups (p = 0.13). The array results were 99.8 % concordant with the pre-determined genotypes. The GS did not differ between the Caucasian participants in the CoRDia SMI plus risk group (n = 66) (p = 0.80) and a sample of UK healthy men (n = 1360). The GS was also associated with LDL-cholesterol (p = 0.05) and family history (p = 0.03) in a sample of UK healthy men (n = 1360).CONCLUSIONS: CHD risk is high in this group of T2D subjects. The risk array is an accurate genotyping assay, and is suitable for estimating an individual's genetic CHD risk. Trial registration This study has been registered at ClinicalTrials.gov; registration identifier NCT01891786.",

keywords = "Adult, Aged, Case-Control Studies, Coronary Artery Disease/diagnosis, Diabetes Mellitus, Type 2/diagnosis, Diabetic Angiopathies/diagnosis, Female, Gene Expression Profiling/methods, Genetic Association Studies, Genetic Markers, Genetic Predisposition to Disease, Humans, Male, Middle Aged, Oligonucleotide Array Sequence Analysis, Phenotype, Polymorphism, Single Nucleotide, Precision Medicine, Predictive Value of Tests, Pregnancy, Risk Assessment, Risk Factors, Time Factors, United Kingdom",

author = "Beaney, {Katherine E} and Ward, {Claire E} and Bappa, {Dauda A S} and Nadine McGale and Davies, {Anna K} and Hirani, {Shashivadan P} and KaWah Li and Philip Howard and Vance, {Dwaine R} and Crockard, {Martin A} and Lamont, {John V} and Stanton Newman and Humphries, {Steve E}",

year = "2016",

month = oct,

day = "3",

doi = "10.1186/s12933-016-0457-7",

language = "English",

volume = "15",

pages = "141",

journal = "Cardiovascular Diabetology",

issn = "1475-2840",

publisher = "BioMed Central",

number = "1",

}

Beaney, KE, Ward, CE, Bappa, DAS, McGale, N, Davies, AK, Hirani, SP, Li, K, Howard, P, Vance, DR, Crockard, MA, Lamont, JV, Newman, S & Humphries, SE 2016, 'A 19-SNP coronary heart disease gene score profile in subjects with type 2 diabetes: the coronary heart disease risk in type 2 diabetes (CoRDia study) study baseline characteristics', Cardiovascular Diabetology, vol. 15, no. 1, pp. 141. https://doi.org/10.1186/s12933-016-0457-7

A 19-SNP coronary heart disease gene score profile in subjects with type 2 diabetes: the coronary heart disease risk in type 2 diabetes (CoRDia study) study baseline characteristics. / Beaney, Katherine E; Ward, Claire E; Bappa, Dauda A S et al.
In: Cardiovascular Diabetology, Vol. 15, No. 1, 03.10.2016, p. 141.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - A 19-SNP coronary heart disease gene score profile in subjects with type 2 diabetes

T2 - the coronary heart disease risk in type 2 diabetes (CoRDia study) study baseline characteristics

AU - Beaney, Katherine E

AU - Ward, Claire E

AU - Bappa, Dauda A S

AU - McGale, Nadine

AU - Davies, Anna K

AU - Hirani, Shashivadan P

AU - Li, KaWah

AU - Howard, Philip

AU - Vance, Dwaine R

AU - Crockard, Martin A

AU - Lamont, John V

AU - Newman, Stanton

AU - Humphries, Steve E

PY - 2016/10/3

Y1 - 2016/10/3

N2 - BACKGROUND: The coronary risk in diabetes (CoRDia) trial (n = 211) compares the effectiveness of usual diabetes care with a self-management intervention (SMI), with and without personalised risk information (including genetics), on clinical and behavioural outcomes. Here we present an assessment of randomisation, the cardiac risk genotyping assay, and the genetic characteristics of the recruits.METHODS: Ten-year coronary heart disease (CHD) risk was calculated using the UKPDS score. Genetic CHD risk was determined by genotyping 19 single nucleotide polymorphisms (SNPs) using Randox's Cardiac Risk Prediction Array and calculating a gene score (GS). Accuracy of the array was assessed by genotyping a subset of pre-genotyped samples (n = 185).RESULTS: Overall, 10-year CHD risk ranged from 2-72 % but did not differ between the randomisation groups (p = 0.13). The array results were 99.8 % concordant with the pre-determined genotypes. The GS did not differ between the Caucasian participants in the CoRDia SMI plus risk group (n = 66) (p = 0.80) and a sample of UK healthy men (n = 1360). The GS was also associated with LDL-cholesterol (p = 0.05) and family history (p = 0.03) in a sample of UK healthy men (n = 1360).CONCLUSIONS: CHD risk is high in this group of T2D subjects. The risk array is an accurate genotyping assay, and is suitable for estimating an individual's genetic CHD risk. Trial registration This study has been registered at ClinicalTrials.gov; registration identifier NCT01891786.

AB - BACKGROUND: The coronary risk in diabetes (CoRDia) trial (n = 211) compares the effectiveness of usual diabetes care with a self-management intervention (SMI), with and without personalised risk information (including genetics), on clinical and behavioural outcomes. Here we present an assessment of randomisation, the cardiac risk genotyping assay, and the genetic characteristics of the recruits.METHODS: Ten-year coronary heart disease (CHD) risk was calculated using the UKPDS score. Genetic CHD risk was determined by genotyping 19 single nucleotide polymorphisms (SNPs) using Randox's Cardiac Risk Prediction Array and calculating a gene score (GS). Accuracy of the array was assessed by genotyping a subset of pre-genotyped samples (n = 185).RESULTS: Overall, 10-year CHD risk ranged from 2-72 % but did not differ between the randomisation groups (p = 0.13). The array results were 99.8 % concordant with the pre-determined genotypes. The GS did not differ between the Caucasian participants in the CoRDia SMI plus risk group (n = 66) (p = 0.80) and a sample of UK healthy men (n = 1360). The GS was also associated with LDL-cholesterol (p = 0.05) and family history (p = 0.03) in a sample of UK healthy men (n = 1360).CONCLUSIONS: CHD risk is high in this group of T2D subjects. The risk array is an accurate genotyping assay, and is suitable for estimating an individual's genetic CHD risk. Trial registration This study has been registered at ClinicalTrials.gov; registration identifier NCT01891786.

KW - Adult

KW - Aged

KW - Case-Control Studies

KW - Coronary Artery Disease/diagnosis

KW - Diabetes Mellitus, Type 2/diagnosis

KW - Diabetic Angiopathies/diagnosis

KW - Female

KW - Gene Expression Profiling/methods

KW - Genetic Association Studies

KW - Genetic Markers

KW - Genetic Predisposition to Disease

KW - Humans

KW - Male

KW - Middle Aged

KW - Oligonucleotide Array Sequence Analysis

KW - Phenotype

KW - Polymorphism, Single Nucleotide

KW - Precision Medicine

KW - Predictive Value of Tests

KW - Pregnancy

KW - Risk Assessment

KW - Risk Factors

KW - Time Factors

KW - United Kingdom

U2 - 10.1186/s12933-016-0457-7

DO - 10.1186/s12933-016-0457-7

M3 - Article (Academic Journal)

C2 - 27716211

SN - 1475-2840

VL - 15

SP - 141

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

IS - 1

ER -

A 19-SNP coronary heart disease gene score profile in subjects with type 2 diabetes: the coronary heart disease risk in type 2 diabetes (CoRDia study) study baseline characteristics

Abstract

Keywords

UN SDGs

Access to Document

Handle.net

Fingerprint

Cite this